Keyphrases
3D Endoanal Ultrasound
13%
5-aminosalicylic Acid (5-ASA)
13%
Adalimumab
29%
Adherence to Therapy
13%
Anti-adalimumab Antibodies
26%
Antibody Formation
14%
Capsule Endoscopy
26%
Clinical Activity
14%
Clinical Response
19%
Confidence Interval
25%
Corticosteroids
29%
Crohn's Disease
100%
Crowdsourcing
13%
Cytomegalovirus
13%
Diagnostic Performance
16%
Drug Concentration
13%
Fecal Calprotectin
26%
Hospitalized Patients
15%
Immunogenicity
19%
Immunomodulator
16%
Inflammatory Activity
14%
Inflammatory Bowel Disease
44%
Loss of Response
14%
Low Albumin
14%
Magnetic Resonance Enterography
13%
Meta-analysis
30%
Narrow Band Imaging
13%
Neoplasia
13%
Neutrophil-to-lymphocyte Ratio
13%
Non-adherence
13%
Novel Biomarkers
13%
Odds Ratio
26%
Phrasing
13%
Place in Therapy
13%
Poeticity
13%
Pooled Analysis
26%
Randomized Controlled Trial
15%
Real-world Experience
24%
Reporting Odds Ratio
13%
Simple Tools
13%
Small Bowel Crohn's Disease
26%
Small Intestine
29%
Syndecan-1
13%
Systematic Meta-analysis
53%
Three-dimensional Endoanal Ultrasound
13%
Time Dependency
13%
Treatment Efficacy
13%
Ustekinumab
29%
Vedolizumab
18%
Web Platform
13%
Medicine and Dentistry
Acute Pancreatitis
13%
Adalimumab
13%
Adenocarcinoma
13%
Albumin
13%
Aminosalicylic Acid Derivative
13%
Biological Marker
17%
Calgranulin
8%
Capsule Endoscopy
28%
Cerebral Sinus Thrombosis
13%
Chromoendoscopy
13%
Combination Therapy
5%
Coronavirinae
13%
Corticosteroid Therapy
13%
Crohn's Disease
53%
Cytomegalovirus
13%
Diagnostic Accuracy
5%
Diseases
13%
Faecal Calprotectin
26%
Feces Incontinence
10%
Hip Fracture
13%
Ibuprofen
13%
Immunomodulating Agent
16%
Infection
8%
Inflammatory Bowel Disease
36%
Internal Anal Sphincter
13%
Lymphocyte
13%
Magnetic Resonance Enterography
13%
Meta-Analysis
30%
Mortality Rate
5%
Muscle Disease
6%
Muscle Injury
6%
Narrow Band Imaging
13%
Neoplasm
13%
Neutrophil
13%
Nilotinib
13%
Odds Ratio
37%
Pancreas Adenocarcinoma
13%
Patient with Crohn's Disease
17%
Patient with Inflammatory Bowel Disease
15%
Pooled Analysis
13%
Retrospective Study
6%
Salvage Therapy
6%
Syndecan 1
13%
Systematic Review
40%
Thrombosis
8%
Ulcerative Colitis
26%
Vedolizumab
13%
White Light Endoscopy
13%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Pancreatitis
13%
Adalimumab
26%
Adverse Event
6%
Aminosalicylic Acid
26%
Biological Product
8%
Combination Therapy
7%
Coronavirinae
13%
Crohn's Disease
61%
Diseases
17%
Drug Concentration
13%
Enteropathy
13%
Hip Fracture
13%
Ibuprofen
13%
Immunogenicity
16%
Immunomodulating Agent
16%
Infection
10%
Inflammation
13%
Inflammatory Bowel Disease
43%
Infliximab
7%
Mortality Rate
6%
Nilotinib
13%
Prospective Study
13%
Randomized Controlled Trial
15%
Remission
9%
Ulcerative Colitis
44%
Ustekinumab
26%
Vedolizumab
13%